Aurinia's Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus NephritisBenzinga • 12/09/21
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)Business Wire • 12/09/21
AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off TodayInvestorPlace • 12/02/21
Aurinia Pharmaceuticals: Potential Blockbuster Justifies Big Pharma M&A InterestSeeking Alpha • 11/22/21
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?Zacks Investment Research • 11/19/21
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare ConferenceBusiness Wire • 11/10/21
Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/21
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company UpdatesBusiness Wire • 11/03/21
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus NephritisBusiness Wire • 11/01/21
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021Business Wire • 10/27/21